Yes, cross reactivity can sometimes be beneficial. For example, T-cell therapies designed to target specific cancer antigens may also recognize and attack cancer cells that express similar but different antigens. This can enhance the overall effectiveness of the therapy. Additionally, cross-reactive immune responses can contribute to the development of broad-spectrum cancer vaccines.